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OBJECTIVE—To assess complication prevalence and identify protective factors in patients
with diabetes duration of $50 years. Characterization of a complication-free subgroup in this
cohortwouldsuggestthatsomeindividualsareprotectedfromdiabetescomplicationsandallow
identiﬁcation of endogenous protective factors.
RESEARCH DESIGN AND METHODS—Cross-sectional, observational study of 351
U.S. residents who have survived with type 1 diabetes for $50 years (Medalists). Retinopathy,
nephropathy, neuropathy, and cardiovascular disease were assessed in relation to HbA1c, lipids,
and advanced glycation end products (AGEs). Retrospective chart review provided longitudinal
ophthalmic data for a subgroup.
RESULTS—A high proportion of Medalists remain free from proliferative diabetic retinopathy
(PDR) (42.6%), nephropathy (86.9%), neuropathy (39.4%), or cardiovascular disease (51.5%).
Current and longitudinal (the past 15 years) glycemic control were unrelated to complications.
Subjectswithhighplasmacarboxyethyl-lysineandpentosidinewere7.2-foldmorelikelytohave
anycomplication.OfMedalistswithoutPDR,96%withno retinopathyprogressionovertheﬁrst
17 years of follow-up did not experience retinopathy worsening thereafter.
CONCLUSIONS—The Medalist population is likely enriched for protective factors against
complications. These factors might prove useful to the general population with diabetes if they
can be used to induce protection against long-term complications. SpeciﬁcA G Ec o m b i n a t i o n s
were strongly associated with complications, indicating a link between AGE formation or pro-
cessing with development of diabetic vasculopathy.
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T
he rising prevalence of diabetes and
its vascular complications is a global
public health issue (1). Studies eval-
uating diabetic patients over 20–30 years
have identiﬁed complication risk factors
including worse glycemic control, longer
diabetes duration, hypertension, and hy-
perlipidemia (2–10). However, other
than glycemic and systemic control, no
clinical or biochemical factors have con-
clusively been shown to protect against
long-term complications.
The Golden Year Study provided a
description of U.K. patients with diabetes
for $50 years (11); however this study
described nephropathy but did not char-
acterize other complications or their rela-
tionship to glycemic control. A more
recent survey of U.S. patients with type
1d i a b e t e sf o r$50 years (Medalists) sug-
gested that over 40% remain free from
multiple complications; however, this
was self-reported data only (12).
This study performed a cross-
sectional characterization of all four vas-
cular complications in a large Medalist
cohort. In addition, we evaluated longi-
tudinal ophthalmic outcomes in relation
to clinical and biochemical markers in-
cludingglycemiccontrol,oxidativestress,
inﬂammatory markers, lipoprotein sub-
populations, and advanced glycation end
products (AGEs). Our goal was to estab-
lish whether or not a substantial propor-
tion of Medalists is protected from
advanced diabetic vascular complications
and, if so, to explore potential correlates




We performed a cross-sectional, observa-
tional study of U.S. residents with at least
50 years of insulin-dependent diabetes.
Longitudinal data on retinopathy progres-
sion was obtained via chart review in
patients followed at the Joslin Diabetes
Center eye clinic (Boston, MA). The Joslin




By 31 December 2007, 443 patients who
received Joslin 50-year medals from 1997
to 2007 had been contacted, and 351
Medalists had completed the single study
visit. Reasons for nonparticipation were
death (n = 32), inability to travel/poor
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Pathophysiology/Complications
ORIGINAL ARTICLE(77.8%, n = 277) received routine care out-
side of the Joslin clinic. Medalists came
from 42 states (Supplementary Table 1),
most commonly Massachusetts (16.0%),
New York (8.6%), Florida (7.1%), and
California (6.8%). All subjects were eval-
uated at the Joslin clinic with medical his-
tory, clinical and ophthalmic exam, and
blood and urine collection.
HbA1c was determined by high-
performance liquid chromatography
(Tosoh G7 and 2.2, Tokyo, Japan);
C-reactive protein measured by particle-
enhanced immunonephelometry (BN
ProSpec Analyzer; Dade Behring, Newark,
DE); lipid proﬁles determined by standard
methods (kits from Roche Diagnostics,
Indianapolis, IN; Denka Seiken, Tokyo,
Japan; AsahiKasei, Tokyo, Japan); total
plasma apolipoprotein A-I concentrations
measured by turbidimetric immunoassay
(Wako Diagnostics, Richmond, VA); and
apolipoprotein A-I containing HDL sub-
populations determined as previously de-
scribed (13). C-peptide was measured by
radioimmunoassay (Diagnostic Systems
L a b o r a t o r y ,W e b s t e r ,T X ) .T o t a lR N A
was isolated from peripheral blood mono-
nuclear cells using TRIReagent (Molecular
Research Center, Inc., Cincinnati, OH).
Standard quantitative real-time PCR
(qPCR) was performed (TaqMan Univer-
sal PCR Master Mix kits, Applied Biosys-
tems) to assess oxidative stress marker
mRNA levels.
Fructose-lysine (measured as furo-
sine), carboxymethyl-lysine (CML), and
carboxyethyl-lysine (CEL) were deter-
mined bygaschromatographymassspec-
trometryusingisotopedilutiontechnique
and an adaptation of Sell’s protocol (14).
Upon hydrolysis, the samples were dried,
spiked with standards of CML-d4 and
CEL-d3, cleaned over LC-18 sep-pack
column, and derivatized into triﬂuoro-
acetic anhydrides. Measured masses
were CML (m/z = 392), CML-d4 (m/z =
396), CEL (m/z = 79), CEL d-3 (m/z =
382),and furosine(m/z =110)quantiﬁed
using CML-d4 standard. Pentosidine was
determined by high-performance liquid
chromatography (15).
Retinopathy
Early Treatment Diabetic Retinopathy
Study (ETDRS)-protocol seven standard
ﬁeld stereoscopic fundus photographs
were graded for clinical severity of diabetic
retinopathy with adjudication of discrep-
ancies. Patients with no-mild nonprolifer-
ative diabetic retinopathy in the more
severely affected eye were compared with
patients with retinal neovascularization or
scatter laser photocoagulation scars indic-
ative of proliferative diabetic retinopathy
(PDR) in either eye. Dates of diabetic
retinopathy progression were obtained for
97 Medalists followed at the Joslin clinic.
Nephropathy
Renal status was based on the average of
urinaryalbumin-to-creatinineratios(ACRs)
from two spot urine samples. Subjects
without microalbuminuria (ACR ,70
mg/mg creatinine) were compared with
those with microalbuminuria (ACR
$70 mg/mg creatinine). Cystatin C levels
were assessed via nephelometry on a
BN ProSpec Analyzer (Dade Behring,
Newark, DE).
Neuropathy
The Michigan Neuropathy Screening In-
strument physical assessment portion
(16) was used to evaluate foot appear-
ance, vibration sensation, muscle stretch
reﬂexes, and monoﬁlament testing.
Scores .2 on the Michigan Neuropathy
Screening Instrument were considered
positive for neuropathy.
Cardiovascular
Medalists reporting a history of coronary
artery disease, angina, heart attack, or
with a prior cardiac/leg angioplasty or
bypass graft surgery were deemed posi-
tive for cardiovascular disease.
Statistical analysis
SAS(v.9.1)wasusedtoperformWilcoxon
rank sum analysis for bivariate analyses
involvingcontinuousvariablesandx
2anal-
ysis to examine categorical variables. Mul-
tivariablelogisticregressionwasperformed
to adjust for possible confounding. Cox
proportional hazards analysis was used to
examine the relationship of variables to di-
abetic retinopathy worsening over time.
Log-rank tests conﬁrmed signiﬁcant differ-
ences in survival distributions between




Medalists (n = 351) had a mean 6 SD age
of 67.5 6 7.5 years and diabetes dura-
tion of 56.5 6 5.7 years. Characteristics
(Table 1) were consistent with type 1 di-
abetes: mean age at diagnosis 11.0 6 6.3
years, BMI 26.0 6 5.1 kg/m
2, and HLA
DR3 or DR4 risk alleles present in 90.8%
ofsubjects.HbA1clevelswere7.361.0%
with HDL levels of 1.62 6 0.51 mmol/L
and LDL levels of 2.22 6 0.63 mmol/L.
Table 1—Baseline characteristics of 50-year Medalist cohort
50-year Medalist subjects: baseline characteristics (N =3 5 1 )
Characteristic
Age (years) 67.5 6 7.5 [51.0–89.3] (351)
Age at diagnosis (years) 11.0 6 6.3 [0–31] (351)
Duration of diabetes (years) 56.5 6 5.7 [50–80] (351)
Sex: male 47.0 (165)
Smoking history 41.1 (138)
History of hypertension 56.1 (185)
ACE inhibitor use 40.1 (140)
Lipid-lowering medication 64.5 (220)
Weight (kg) 72.8 6 15.0 [41.3–131.5] (347)
Height (m) 1.67 6 0.10 [1.20–1.93] (347)
BMI (kg/m
2) 26.0 6 5.1 [15.9–58.0] (347)
Insulin dose (units/kg) 0.46 6 0.17 [0.01–1.13] (334)
sBP (mmHg) 134.5 6 19.7 [90–190] (271)
dBP (mmHg) 60.9 6 8.3 [37–83] (271)
Mean arterial pressure (mmHg) 85.4 6 10.2 [59.3–111.3] (271)
Current HbA1c (%) 7.3 6 1.0 [5.0–14.0] (342)
Longitudinal HbA1c (%) 7.7 6 1.0 [5.7–10.6] (73)
Total cholesterol (mg/dL) 163.9 6 33.9 [76–299] (313)
HDL (mg/dL) 62.4 6 19.5 [28–142] (313)
LDL (mg/dL) 85.9 6 24.2 [14–187] (313)
Triglycerides (mg/dL) 78.3 6 46.1 [17–391] (313)
C-peptide .0.4 ng/mL 6.0 (19)
Data are mean 6 SD [range] (N)o r%( N).
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Sun and AssociatesSix percent of subjects demonstrated ran-
dom C-peptide .0.13 nmol/L.
Complications
High proportions of Medalists remained
free from PDR (49.4%), nephropathy
(86.9%), neuropathy (39.4%), or cardio-
vasculardisease(51.5%)(Fig.1A).Of255
subjects forwhomallthreemicrovascular
complications were characterized, 21.2%
were free ofPDR,nephropathy,andneu-
ropathy. A bimodal diabetic retinopathy
distribution was present with 40.2%
having no-mild nonproliferative diabetic
retinopathy and 48.5% having PDR
(Fig.1B).Incontrast,86.9%ofMedalists
had no nephropathy (ACR ,70 mg/mg
creatinine) with only 4.7% exhibiting
proteinuria (ACR $300 mg/mg creati-
nine).
Factors associated with complications
after 50 years of diabetes differ from
those in shorter duration diabetes
Factors associated with individual com-
plications were not necessarily consistent
with those established for shorter dura-
tion diabetes (Supplementary Table 2).
No signiﬁcant relationship was found be-
tween glycemic control and any compli-
cation in the Medalist cohort.
Figure 1—A: Prevalence of micro- and macrovascular diabetes complications in the 50-year Medalist cohort. mod, moderate; microalb, micro-
albuminuria; NPDR, nonproliferative diabetic retinopathy. B: Bimodal distribution of diabetic retinopathy severity in the Medalist cohort. DR,
diabetic retinopathy; HRC, high-risk characteristics; Mod, moderate; NPDR, nonproliferative diabetic retinopathy.
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Complications in extreme duration diabetesLongitudinal glycemic control (HbA1c
from 1993 onward) was assessed for 73
Medalists (20.1%) followed at the Joslin
clinic. The average number of HbA1c mea-
surements was 20.4. Mean HbA1c was
7.7%. This subgroup did not differ from
the overall cohort on age, age of diagnosis,
duration of diabetes, blood pressure, lipid
proﬁle, or complication status. Current
HbA1c was highly correlated with longitu-
dinal HbA1c (r =0 . 8 2 ,P , 0.001). Consis-
tent with the lack of association between
current HbA1c and complications, no sig-
niﬁcant relationship was found between
longitudinal HbA1c and complications.
Systolic (sBP) and diastolic (dBP)
blood pressure, also typically associated
with complications in subjects with
shorter duration disease, did not correlate
with microvascular complications in the
Medalists.Longerdurationofdiabeteswas
associated with increased nephropathy
(P = 0.009), neuropathy (P = 0.009), and
cardiovascular disease (P = 0.03), but not
retinopathy. Cardiovascular disease was
more prevalent in subjects with lower
sBP (P = 0.01) and mean arterial pressure
(P = 0.004), lower heart rate (P = 0.002),
and lower total cholesterol (P , 0.001) or
LDL (P , 0.001), likely because of high
percentages of these subjects on hyperten-
sive and/or lipid-lowering medications.
Subjects withnephropathy weremore
likely to report a history of smoking (P ,
0.001). Neuropathy was related to older
current age (P , 0.001), increased height
(P = 0.003),andheavierweight(P =0.03).
Macrovascular complications were related
to older current age (P = 0.02).
Lipoprotein subpopulations were
assessed(SupplementaryTable2).Higher
rates of cardiovascular disease were re-
lated to elevations in lipoprotein(a) (P =
0.04) and decreases in HDL (P , 0.001).
Higher levels of pre-b2 HDL were asso-
ciated with each complication, but these
elevations were statistically signiﬁcant
only for nephropathy (P = 0.02) and car-
diovascular disease (P =0 . 0 0 6 ) .
Inﬂammatory marker evaluation re-
vealed that higher levels of C-reactive
protein were observed for cardiovascular
disease (P , 0.001), and signiﬁcant ele-
vations of soluble vascular cell adhesion
molecule-1 were present in those with
neuropathy (P = 0.02) and nephropathy
(P = 0.05) but not retinopathy. Other in-
ﬂammatorymarkersdidnotdifferbetween
subjects with and without complications.
Similarly, oxidative stress biomarkers in-
cluding urinary 8-isoprostane and mRNA
levels of superoxide dismutase, heme
oxygenase1,catalase,andglutamate-cyste-
ine ligase catalytic subunit were not associ-
ated with complication status.
Long-term data on retinopathy
progression and stabilization
Factors associated with prolonged protec-
tion from complications were evaluated in
97 Medalists with median ophthalmic
follow-up of 23 years (Q1, Q3: 8, 31
years), number of visits 33 (4, 63 visits),
and diabetes duration 56 years (53, 61
years). This group was not signiﬁcantly
different from the cross-sectional cohort
in age, age at diagnosis, current or longi-
tudinal HbA1c, sBP or dBP, or heart rate,
butitdidhavehighertotalcholesterollev-
els (4.46 vs. 4.25 mmol/L, P = 0.03).
Over time, 46 patients (47.4%) with-
out PDR at baseline progressed to PDR
(mediantimetoPDR:38.4years). Subjects
who developed PDR had higher sBP than
those who did not develop PDR (144 vs.
125 mmHg, P = 0.02), but there was no
relationship between PDR development
and current or longitudinal HbA1c, age,
age at diagnosis, diabetes duration, sex,
BMI, dBP, heart rate, or lipid parameters.
Of 25 subjects with no baseline di-
abetic retinopathy in either eye, 11 (44%)
remainedfreeofPDRinbotheyesatthelast
visit. The retinopathy progression rate was
slowerinMedalistswhodidnotprogressto
PDR in either eye as compared with those
that did (P , 0.001) (Fig. 2). Of the 24
Medalists (52%) whose retinopathy did
not worsen over the ﬁrst 17 years of
follow-up, 23 (96%) did not worsen
thereafter with follow-up out to a mini-
mum duration of diabetes of 50.4 years
and median follow-up of 13 years (Q1,
Q3: 6, 27 years).
Complication associations with
AGEs
Given the lack of correlation between
current HbA1c and complications, we as-
sessed markers of long-term glycemic
control in the Medalists by evaluating
the early glycation product fructose-
lysine/fructosamine and AGE concentra-
tions including CEL, an AGE derived
from methylglyoxal; pentosidine, a glyc-
oxidation product; and CML, a glycoxi-
dation and advanced lipoxidation product.
CELandfructose-lysineCMLweresignif-
icantly elevated in the Medalists as com-
pared with nondiabetic, age-matched
control subjects (n =2 3 ,m e a na g e6 7 . 7
years) (Supplementary Table 3).
A combined biomarker of CEL and
pentosidine was highly associated with
complication status. Subjects with both
CEL and pentosidine $median levels
(“high CEL and pentosidine”:C E L$5.3
mmol/mol lysine and pentosidine $1.0
pmol/mg protein) were the most likely
to have any complication (P = 0.001) or
Figure 2—Worsening retinopathy in Medalists who do and do not progress to PDR. DR, diabetic
retinopathy; sig, signiﬁcant. (A high-quality color representation of this ﬁgure is available in the
online issue.)
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Sun and Associatessufferfromnephropathy(P=0.007),neu-
ropathy (P = 0.005), or cardiovascular
disease (P = 0.002). Subjects with either
CEL or pentosidine (but not both) at or
above the median had an intermediate
risk of severe complications, and subjects
with both CEL andpentosidinebelow the
median had the lowest complication risk.
The odds of complications in Medalists
with high CEL and pentosidine as com-
p a r e dw i t ht h o s ew i t hl o wC E La n d
pentosidinewere7.2-foldforanycompli-
cation, 1.3-fold for retinopathy, 3.1-fold
fornephropathy,2.5-foldforneuropathy,
and 2.3-fold for cardiovascular disease
(Fig. 3A).
TherelationshipbetweencurrentAGE
concentrations and risk of progression to
PDR was examined in Medalists with
longitudinal follow-up. Increased risk of
PDR was seen in subjects with high CEL
and pentosidine as compared with the rest
of the cohort (P = 0.05) (Fig. 3B). A com-
bination biomarker that also included
CML and fructose-lysine segmented by
median (“low CML and fructose-lysine”:
CML ,59.8 and fructose-lysine ,1,004
mmol/mol lysine) was even more strongly
associated with PDR outcome (P = 0.02)
(Fig. 3C). None of the four subjects with
lowCELandpentosidine(CELandpento-
sidine levels below the median) and
high CML and fructose-lysine (CML and
fructose-lysine levels above the median)
progressed to PDR over the course of
follow-up. Conversely, ﬁve of seven sub-




with unexpectedly few complications
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PDR development by CEL and pentosidine levels. DM, diabetes; Pent, pentosidine. C: Progression to PDR in patients grouped by combined CEL and
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Complications in extreme duration diabetesdespite extremely long duration diabetes,
theMedalistgroupappearstobeenriched
for factors protective against morbidity
and mortality. The survival bias inherent
in studying the Medalist cohort thereby
permits evaluation of complication-
protective factors in addition to a con-
ventional assessment of risk factors. The
clinical results from these cross-sectional
and longitudinal studies provide strong
support for the existence of endogenous
factors in some individuals that can re-
duce and even prevent diabetes compli-
cations. We have also demonstrated that
individualswhodonotdevelopadvanced
retinopathy over long durations of diabe-
tes are unlikely to experience further
worsening of retinopathy once they have
had 17 or more years of follow-up. This
ﬁnding indicates that protective mecha-
nisms against complication development
are activated early and chronically in the
course of the disease.
Behavioral skills leading to improved
control of blood glucose, blood pressure,
and cholesterol are clearly crucial in
preventing complications in diabetic pa-
tients in general. Indeed, the mean Med-
alist HbA1c of 7.3% indicates good
glycemic control in many subjects, and
it is possible that Medalists without com-
plications had better control during early
diabetes than those who developed com-
plications. However, the existence of ad-
ditional unique protective factors in some
Medalistsissupportedbythefactthatgly-
cemic control was not related to compli-
cationsinthiscohort despiteawiderange
of HbA1c (5–14%). It is also important to
note that most Medalists developed dia-
betes when strict glycemic control was
neither possible nor the standard of med-
ical care. By 1993, when the results of the
DiabetesControlandComplicationsTrial
(DCCT) were ﬁrst reported, the most re-
cently diagnosed Medalist had already
had diabetes for 36 years. Thus, it is un-
likely that most Medalists instituted cur-
rent standard strict glycemic control of
HbA1c within the ﬁrst few decades of di-
agnosis. The lack of retinopathy progres-
sion in the subset of Medalists who have
been followed chronically at the Joslin
clinic suggests that protective factors
may have several roles including neu-
tralization of initiating toxic effects of
hyperglycemia, combating mechanisms
responsibleforcomplicationprogression,
and even facilitation of glycemic or meta-
bolic memory. Future longitudinal study
of glycemiccontrolin theMedalist cohort
will provide important information on
the effect of endogenous protective fac-
tors on metabolic memory.
The AGE results conﬁrm a robust
association with complications and sug-
gest AGE speciﬁcity in associations with
both protection from and risk for devel-
opmentofcomplications.Theassociation
of complications with CEL implicates
increased methyglyoxal production,
which itself is associated with various
cellular and matrix dysfunctions (17),
whileincreasedpentosidinelikelyreﬂects
increased ascorbic acid degradation be-
cause of oxidant production (18). These
data are the ﬁrst to suggest that speciﬁc
AGEs may decrease the risk for diabetes
complications because high current CML
and fructose-lysine concentrations were
negatively correlated with PDR develop-
ment. Previous reports indicated that
AGEs and their precursors may be impor-
tant in the pathogenesis of diabetes
complications (19–25); however it is un-
expectedthatlowercurrent levelsof CML
andfructose-lysineareinverselyrelatedto
PDR development in light of reports in-
dicating an association between eleva-
tions of these AGEs measured in other
tissues and retinopathy (24). Previous
studies ﬁnding positive correlations be-
tween AGEs and diabetes complications
have measured AGEs in skin samples or
other target tissues (24). In contrast, this
study examined plasma AGE concentra-
tions. Given the lack of relationship be-
tween HbA1c and complications in this
group, it is possible that an adaptive
mechanism, which can alter the process-
ing of CML and fructose-lysine, may pro-
vide protection against development of
PDR and possibly other complications of
diabetes.
Several limitations are present in this
study. The presence of retinopathy and
nephropathy were studied in detail,
whereas neuropathy and cardiovascular
complications were only estimated clini-
cally. Despite these limitations, known
risk factors for neuropathy (height and
male sex) and cardiovascular disease
(dyslipidemia) were conﬁrmed, indi-
cating a reasonable assessment of these
complications.Anotherlimitationderives
from the study’s cross-sectional nature,
which prevents conclusions concerning
the predictive value of AGEs for compli-
cation development. Finally, because of
the nature of this unique cohort, there is
difﬁculty inestablishinganadequatecon-
trol group for external comparison. The
Medalist group as a whole must have sur-
vival characteristics that allowed them to
outlive many peers with diabetes. It is dif-
ﬁcult, however, to characterize a compari-
son cohort in the same rigorous manner as
has been done for the Medalists—
including obtaining blood samples and
fundus photographs—of age- and sex-
matched patients diagnosed during the
sametimeframewhoarealreadydeceased.
Thus, we have chosen as a ﬁrst step in this
study to focus on subjects with and with-
out complications within the Medalist co-
hort in order to identify factors associated
with complications or protection. Future
studies, already underway, may focus on
further comparisons of the Medalist co-
hort as a whole to pre-established groups
of shorter-lived patients with diabetes in
order to establish factors allowing survival
of this group over a time period in which
systemic control of diabetes was not em-
phasized as heavily as it is in the post-
DCCT era. Given the unique nature of
the Medalist cohort, it will be important
to investigate and validate these ﬁndings
ingroupsofpatientswithshorterduration
diabetes and faster progression of micro-
vascular complications in order to assess
generalizability to the overall population
of diabetic patients. However, even if pro-
tection factors are unique to the select
Medalist group, future mechanistic under-
standing and target identiﬁcation arising
fromtheseresultsmayprovidenovelpre-
ventative interventions pertinent to all
patients with diabetes.
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